Ideaya Biosciences
Clinical trials sponsored by Ideaya Biosciences, explained in plain language.
Precision medicine oncology company developing targeted therapies.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New cancer drug IDE161 enters human testing Results expected Oct 2026 (estimated)
- New drug IDE397 targets Hard-to-Treat cancers in early trial Results expected Jan 2027 (estimated) May already have reported ↗
- New drug cocktail aims to fight deadly eye cancer Results expected Jan 2027 (estimated) May already have reported ↗ 🚀 Make-or-break
- New drug targets rare genetic cancers in early trial Results expected Jan 2027 (estimated) May already have reported ↗
- New pill could save eyes from melanoma surgery Results expected Apr 2027 (estimated) May already have reported ↗
-
New cancer drug IDE161 enters human testing
Disease control OngoingThis early-stage trial is testing a new drug called IDE161, alone or with the immunotherapy pembrolizumab, in adults with advanced solid tumors (like breast, ovarian, prostate, or lung cancer). The main goals are to check safety, find the right dose, and get a first look at wheth…
Phase 1 • Sponsor: IDEAYA Biosciences • Aim: Disease control
Last updated Jul 15, 2026 00:00 UTC
-
New drug IDE397 targets Hard-to-Treat cancers in early trial
Disease control OngoingThis Phase 1 trial tests a new drug called IDE397, alone or with another drug (sacituzumab govitecan), in adults with advanced solid tumors that have a specific genetic change (MTAP deletion) and have stopped responding to standard treatments. The study aims to find safe doses an…
Phase 1 • Sponsor: IDEAYA Biosciences • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
New pill could save eyes from melanoma surgery
Disease control OngoingThis phase 2 trial tests darovasertib, a daily pill, in 160 people with uveal melanoma (a rare eye cancer). The drug is given before and after standard treatments like surgery or radiation. The main goals are to see if the pill can shrink tumors enough to avoid eye removal, reduc…
Phase 2 • Sponsor: IDEAYA Biosciences • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
New drug cocktail aims to fight deadly eye cancer
Disease control OngoingThis study tests a combination of two oral drugs, darovasertib and crizotinib, against standard treatments (immunotherapy or chemotherapy) in 420 people with a specific type of advanced eye melanoma that has spread. Participants must have a certain genetic marker (HLA-A2 negative…
Phase 2/3 • Sponsor: IDEAYA Biosciences • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC